PD-L1 expression

Lenvatinib plus pembrolizumab demonstrated improved ORR compared with sunitinib monotherapy in treatment-naïve patients with advanced RCC regardless of risk status or PD-L1 expression. @motzermd @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/p1LcSl5Czk (@OncLive)

🚨Very high PD-L1 expression (>90%), high TMB, and increased CD8+PD1+ T cells density associate w/ prolonged benefit from CRT ➡️durvalumab in stage III #NSCLC. Out in @NatureComms our multi-center analysis led by🌟 @alessi_joao. #biomarkers can help⬆️outcomes. @OncoAlert #LCSM (@BiagioRicciutMD)

Adj nivolumab vs plc in resected esophageal or GEJ cancer following neoadjuvant CRT: biomarker analyses from CheckMate 577 by R. Kelly at #WCGIC2023 👉Benefit in multiple (inflammatory) subgroups 👉Increase in PDL1 expression in 51% post-CRT @myESMO @WCGIC (@ArndtVogel)

Adj nivolumab vs plc in resected esophageal or GEJ cancer following neoadjuvant CRT: biomarker analyses from CheckMate 577 by R. Kelly at #WCGIC2023 👉Benefit in multiple (inflammatory) subgroups 👉Increased PDL-1 expression in 51% post-CRT @myESMO @WCGIC (@ArndtVogel)

AVM: SCARLET Study WJOG14821L Single arm Ph2 sotorasib + chemo in KRAS G12c nonsquamous mNSCLC 🔹N=30, chemo & KRAS inhibitor naive 🔹1ry endpoint ORR: 88.9% No diff in ORR by PD-L1 expression mPFS and mOS NR but limited f/u at analysis of only 4 mo #LCSM #ASCO23 @AnaVManana (@OncLive)

Masterful presentation by @motzermd reporting subgroup analyses from #CheckMate914 (part A). Exploratory analyses suggest tumor PD-L1 expression influenced outcome of adjuvant IPI+NIVO in pts with localized #RCC at high risk of post-nephrectomy relapse #ASCO23 @OncoAlert (@DrChoueiri)

Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses. @ASCO #ASCO23 While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit… https://t.co/5ziP6nUPzT (@ZiadBakouny)

#ASCO23 @ASCO Abs#8509 Focus on perioperative therapy in #LCSM #RapidAbstracts Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (#EASTENERGY) ➡️ N=24 ➡️ Shows feasibility https://t.co/kyigzPc9y7 @OncoAlert @HemOncToday (@CharuAggarwalMD)

@RutgersCancer’s Dr. Patrick Boland @PMBolandMD & colleagues present “Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced #gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2… https://t.co/R7fEFg5Vxy (@RutgersCancer)

Professor George Simon starting to elucidate how we treat NSCLC based on PD-L1 expression. Seems to be easy, when in fact, it is very difficult and more data coming up. Moreover, checkpoint inhibitor resistance. @IASLC @OncLiveSOSS #stateofscience @MoffittNews @LuisRaezMD (@EdgardoSantosMD)

🌟Just out in @JCO_ASCO pivotal paper using proteomics to quantify PD1/PDL1 interaction shows: 👉PD1/PDL1 Complex levels do NOT correlate with PD-L1 IHC Expression! 👉PD1/PDL1 engagement Is predictive of pt response to IO #LCSM #some @OncoAlert @ASCO https://t.co/rjkrHaqcPe (@g_mountzios)

Reed-Sternberg cells (malig cell in Hodgkin) strongly express PDL1 due to amplification of 9p24 which contains the PDL1 & PDL2 locus. An exuberant microenvironment includes plenty of PD1+ T-cells and other immune cells. (fig: Roemer et al, JCO 2018) (@graham74GC)

5/8 In examining clinical outcomes to PD-(L)1 based therapies, there was no difference between patients with ATM mutant and ATM wild-type NSCLC, despite increased TMB/PD-L1 expression (though higher rate of KRAS/STK11 co-mutations) in the ATM mutant subset. (@BiagioMd)

6/8 By contrast, concurrent ATM/TP53 mutations were associated with increased TMB, high PD-L1 expression, and improved ORR and PFS with PD-(L)1 blockade in patients NSCLC. (@BiagioMd)

2/8 We identified 562 deleterious ATM mutations in 9.7% (503/5172) of NSCLC samples. ATM mutations were associated with high TMB, increased PD-L1 expression and were enriched in KRAS, STK11, and ARID2 co-mutations. TP53 and EGFR mutations were enriched in ATM wild-type NSCLCs. (@BiagioMd)

For patients with NSCLC treated with mono or dual ICI, PD-L1 expression was more predictive of benefit for non-squamous than squamous. https://t.co/MfWYwpDglL (@MLPOncoData)

🚨 Tislelizumab improves survival ( 17mo vs 10 mo ) in metastasic esophageal SCC 👉 Benefit regardless of PDL1 expression. 👉Flexible chemo backbones 🔹 Impressive data compared to other IOs. @BijoyTelivala @TheLancetOncol @Cancer_Free_IND @SuyogCancer https://t.co/4AdmQr4yv6 (@saadvikdr)

NEOTORCH included 90% men, 78% squamous NSCLC. This is a far cry from AEGEAN (46% squamous) and CheckMate 816 (49% squamous). Includes 67% stage IIIA and 32% stage IIIB. 66% were PDL1 positive (no breakdown on high vs low yet). #ASCOPlenarySeries (@StephenVLiu)

💭 #JCO #Correspondence: Validity of meta-analytical estimates and hazard ratios quantifying survival benefit of Immunochemotherapy in low programmed death ligand 1-expressing #EsophagealSquamousCellCarcinoma 👉 https://t.co/QJ9BZI7gBr #esocsm #ImmunoOnc (@JCO_ASCO)

#TexasLung23 Dr Tina Cascone Conference Co-chair sets the stage for Neoajuvant Chemo-IO in lung cancer: What we have learned & unanswered questions about role of PDL1 expression, role of postop IO therapy. @IDEOlogyHealth @TLCconference #lcsm @StephenVLiu (@Latinamd)

Nivolumab & relatlimab demonstrated clinical benefit w/ a manageable safety profile in pts w/ advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression. @evanlipson @hopkinskimmel #melsm https://t.co/K7sJD0Bhlq (@OncLive)

Nivolumab & relatlimab demonstrated clinical benefit w/ a manageable safety profile in pts w/ advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression. @evanlipson @hopkinskimmel #melsm https://t.co/yG5OlPCryK (@OncLive)

Just out - PD-L1 in cytology, an everlasting question! Thanks to #LCSM #MolOncology Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumor cells and tumor tissue in non-sm… https://t.co/y26BGJfRru (@MartinReck2)

Thrilled to report new patent @uspto USSN: 11,574,404 "Predicting Recurrence & Overall Survival using #Radiomic features correlated with PD-L1 expression in early stage non-small cell lung cancer". Kudos to co-inventors @PrateekPrasana @pranjal31vaidya @VamsiVelcheti @hopelessk (@anantm)

Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay https://t.co/n65VoUKPIS No major genomic differences in TNBC according to PDL1 status (CPS). The biology behind PD-L1 expression is still obscure! ()

If you missed it, EU CHMP will limit $REGN Libtayo + chemo in 1L NSCLC to PD-L1 expressers. Empower-Lung-3 trial showed HR=1.01 in PD-L1 <1%, per #Esmo21, but FDA approved in all-comers anyway... (@JacobPlieth)

KEYNOTE-189 : 5-year outcomes: The longest follow-up of a combo of IO + chemo as 1st line for NS-NSCLC. Pembro + pem-platinum continued to demonstrate prolonged OS regardless of PDL1 expression Very proud to participate in this trial. @Hospital_FJD @UAM_Madrid @OncoAlert @AEACaP (@ManuelDomine)

Assessment of PD-L1 expression “is hurting more than helping patients” with #KidneyCancer, according to @DrChoueiri #GU23 (@Prof_IanD)

Companies push markers like PD-L1 expression because they have positive predictive value and enrich for responders. Clinicians don’t care: we want markers with *negative* predictive value, ie we want to know who should *not* get IO. Maybe there’s a clue here. #GU23 @apolo_andrea (@Prof_IanD)

What do we know about long term responders to immunotherapy in NSCLC? Report in #JTOCRR looked at 29 pts who responded for >2y. No significant differences in PD-L1 expression or serum drug concentration seen at 3m and 6m into therapy. @JTOonline https://t.co/CDFyOL1vLx (@StephenVLiu)

Probing the mononuclear phagocyte network in classical #Hodgkin. • Diverse & spatially polarised: conventions MCs, macroph & DC2 localise with HRS; plasmacytoid DC excluded • Inhib mols PDL1, TIM3, IDO all expressed • Assoc with Rx failure. https://t.co/Jxep9Ow0Y4 (@graham74GC)

An expert discusses how the approval of adjuvant pembrolizumab expands treatment to include patients with IB, II, III, and IIIA resected, early-stage, non–small cell lung cancer regardless of PD-L1 expression. #NSCLC | @YaleMed @DrRoyHerbstYale https://t.co/lC0gtvqjEz (@CancerNetwrk)

Dr. @FedericoCappuz1 discusses use of adjuvant IO for respected NSCLC. Atezolizumab approved based on IMpower010 and pembrolizumab approved based on KEYNOTE 091. How should we use PDL1 expression given these 2 different datasets? MRD coming soon to guide therapy? #ILCDebates2023 (@StephenVLiu)

1. #KN091 #PEARLS by @peters_solange : Pembrolizumab in adjuvant settings and after chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA NSCLC. Approved for PDL1 expressions. - DFS- 58.6 v 42 mos - HR = 0.76 #LCSM https://t.co/AK48NqZbav (@OncBrothers)

Another adjuvant option in lung cancer @FDAOncology approves #pembrolizumab as adjuvant tx for NSCLC (based on #KEYNOTE091 N=1177 RCT Stage IB-IIIA (regardless of PDL1 expression) best DFS on those receiving chemo: 58.7 mos vs 34.9 mos @oncalert #lcsm https://t.co/CZGOMXDP6N (@Latinamd)

Absolutely: the data with the anti-Trop2 ADC Dato-DXd for TNBC is very promising! In the #BEGONIA phase 1b/2 trial, 1L Dato-DXd+durva achieved an impressive ORR of 73%, with durable responses observed regardless of PD-L1 expression. (@PTarantinoMD)

🚨@US_FDA approves pembrolizumab for adjuvant treatment after resection & platinum-based chemo for stage IB (T2a ≥4 cm), II-IIIA NSCLC, per KEYNOTE-091 ✨irrespective of PD-L1 expression, despite subset data✨ #lcsm, what is our take-away & what to do in clinic? @OncoAlert (@esinghimd)

Pembrolizumab is now approved by the @US_FDA for adjuvant therapy. Note that there is no restriction by stage or PDL1 expression, unlike the approval for atezolizumab. I don’t think this rather broad approval including in PDL negative population is helpful #LCSM (@CharuAggarwalMD)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC - Annals of Oncology https://t.co/TUj6QtDtHl (@bpiperdi)

#GI23. Her2 low gastric/esophageal cancer has higher PDL1 expression, a different molecular profile that may contribute to a favorable immune microenvironment. (@badrinabeel)

Pathologists when medical oncologists ask repeatedly if there is *really* no her2 or PDL1 expression in a specimen #GI23 (@marklewismd)

Interestingly analysis, the triple-negative #breastcancer has high #immunogenicity due to increased positivity to express TIL and PD-L1. @Onco_IdISSC @MolMedLabuO @BCancerAcademy https://t.co/Gru1rfzb2B (@Dr_Ivanoncologo)